吉药控股集团股份有限公司 内部控制审计报告 德皓内字[2025]00000119 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 吉药控股集团股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 北京德皓国际会计师事务所（特殊普通合伙） 北京市丰台区西四环中路 78 号院首汇广场 10 号楼[100141] 电话:86(10)6827 8880 传真:86(10)6823 8100 内 部 控 制 审 计 报 告 德皓内字[2025]00000119 号 吉药控股集团股份有限公司全体股东： 我们接受委托，对吉药控股集团股份有限公司（以下简称吉药控 股公司）2024 年 12 月 31 日的财务报告内部控制进行审计。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有 ...

吉药控股集团股份有限公司 关于营业收入扣除事项的 专项核查意见 德皓核字[2025]00000938 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 吉药控股集团股份有限公司 关于营业收入扣除事项的 专项核查意见 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | | | | | 北京德皓国际会计师事务所（特殊普通合伙） 北京市丰台区西四环中路 78 号院首汇广场 10 号楼[100141] 电话:86(10)6827 8880 传真:86(10)6823 8100 关于营业收入扣除事项的 专项核查意见 德皓核字[2025]00000938号 吉药控股集团股份有限公司： 我们接受委托，对吉药控股集团股份有限公司（以下简称吉药控 股 公司） 2024 年 度 财 务 报 表 进 行 审 计 ， 并 出 具 了 德 皓 审 字 [2025]00001452 号审计报告。在此基础上我们检查 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥63,743,551.35, a decrease of 15.53% compared to ¥75,460,849.87 in the same period last year[5] - The net loss attributable to shareholders was ¥45,174,602.67, representing a 10.58% increase from a loss of ¥40,853,954.75 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0678, reflecting a decrease of 10.60% from -¥0.0613 in the same quarter last year[5] - Operating profit for the current period is -¥52,695,244.21, compared to -¥50,350,649.71 in the previous period, indicating a slight increase in losses[24] - Net profit for the current period is -¥62,769,455.79, compared to -¥60,502,670.21 in the previous period, reflecting a worsening of approximately 3.8%[24] - The total comprehensive loss amounted to -62,769,455.79 CNY, slightly higher than the previous period's loss of -60,502,670.21 CNY, reflecting an increase of about 3.8%[25] Cash Flow and Liquidity - The net cash flow from operating activities was -¥10,598,571.43, a significant decline of 1,087.19% compared to a positive cash flow of ¥1,073,613.47 in the prior year[5] - Cash inflows from operating activities totaled 50,142,889.64 CNY, down from 78,413,126.79 CNY in the previous period, a decline of about 36.0%[27] - Cash and cash equivalents decreased from ¥24,509,161.98 to ¥15,756,568.83, a decline of about 35.5%[20] - Cash and cash equivalents at the end of the period were 7,789,702.73 CNY, significantly lower than 26,700,040.88 CNY at the end of the previous period, a decrease of approximately 70.8%[29] - The net cash flow from financing activities was 1,857,433.37 CNY, down from 3,021,352.18 CNY in the previous period, indicating a decline of about 38.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,428,970,156.95, down 1.08% from ¥1,444,512,507.38 at the end of the previous year[5] - Total liabilities increased from ¥2,947,890,187.24 to ¥2,996,904,097.04, an increase of about 1.7%[21] - The company has a negative retained earnings of -¥3,060,755,075.42, worsening from -¥3,015,580,472.75 in the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,056, with the top ten shareholders holding a combined total of 38,364,481 shares[10] - The top ten shareholders hold a total of 9,487,015 shares, representing 0.83% of the total shares outstanding[11] - The company has not disclosed any changes in the participation of major shareholders in margin financing or securities lending activities[12] - The company has not identified any related party relationships among the top ten shareholders[11] - The company has a total of 4,605,450 restricted shares held by other shareholders, with 2,550 shares released during the period[14] - As of March 31, 2025, the company reported a significant increase in restricted shares, totaling 21,913,249 shares, up from 12,768,750 shares[14] Operational Challenges - The company reported a significant decrease in cash received from sales, totaling ¥37,979,527.05, down 44.29% from ¥68,171,452.73 in the previous year[9] - Sales expenses increased by 64.20% to ¥10,976,344.75, primarily due to increased sales promotion efforts during the reporting period[9] - The company recorded a government subsidy of ¥128,842.82, a decrease of 57.99% from ¥306,713.63 in the previous year[9] - The company faces a significant delisting risk as its stock price has been below 1 RMB for twenty consecutive trading days, leading to a notice from the Shenzhen Stock Exchange regarding the termination of its stock listing[17] - The company has initiated a bankruptcy reorganization process to alleviate historical debt pressure and restore profitability, with the court approving the pre-reorganization on November 27, 2023[15] - The company is actively working with local government to manage its financial restructuring and improve its operational capabilities[15] Future Outlook - The company has not provided any guidance on future performance or new product developments in the recent conference call[15]

Financial Performance - The company's operating revenue for 2024 was ¥333,330,280.33, a decrease of 3.69% compared to ¥346,106,530.05 in 2023[21] - The net profit attributable to shareholders for 2024 was a loss of ¥439,433,948.13, representing a 25.80% increase in losses from ¥349,309,644.16 in 2023[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥410,060,141.00, which is 41.51% worse than the loss of ¥289,768,468.85 in 2023[21] - The total profit for the period was -¥625,067,615.87, representing a decline of 41.30% year-over-year[41] - The net profit attributable to shareholders was -¥439,433,948.13, down 25.80% from the same period last year[41] - The company reported a net loss of ¥445.91 million for the year 2023, with equity attributable to shareholders of the parent company at -¥280.67 million[137] - The company has faced significant financial deterioration, with negative net profits for several consecutive years[137] - As of December 31, 2023, the company's total equity was -¥807.13 million, indicating ongoing financial instability[137] Assets and Liabilities - The total assets at the end of 2024 were ¥1,444,512,507.38, a decrease of 24.52% from ¥1,913,801,546.81 at the end of 2023[21] - The company's net assets attributable to shareholders at the end of 2024 were negative at ¥-776,519,451.36, a decline of 176.66% from ¥-280,671,891.27 at the end of 2023[21] - The company reported total assets of 1.445 billion and total liabilities of 2.948 billion, resulting in a debt-to-asset ratio of 204.08%[74] - Short-term borrowings amounted to 612,096,046 yuan, representing 42.37% of total liabilities, an increase from 38.01%[60] - Long-term borrowings were recorded at 676,059,729.74 yuan, which is 46.80% of total liabilities, up from 35.34%[60] Cash Flow - The cash flow from operating activities for 2024 was a net outflow of ¥36,031,399.80, which is 7.44% worse than the outflow of ¥33,535,035.85 in 2023[21] - Cash inflow from operating activities decreased by 9.64% to ¥265,549,005.63, while cash outflow decreased by 7.89% to ¥301,580,405.43[54] - Net cash flow from investment activities improved by 65.21%, primarily due to increased cash from investment income[54] - Cash flow from financing activities decreased by 32.77% to ¥45,369,606.28, attributed to reduced cash from borrowings[54][55] Legal and Compliance Issues - The audit report for 2024 issued by Beijing Dehao International CPA indicates an inability to express an opinion, highlighting significant risks to the company's ability to continue as a going concern[5] - The company faced severe liquidity issues, leading to overdue loans and multiple lawsuits, which significantly impacted its operations[5] - The company is facing multiple lawsuits due to overdue debts, leading to the freezing of several bank accounts and assets, which may result in judicial auctions of shares[75] - The company is currently in litigation with multiple parties, including Guoyao Holdings and Zhongmin Investment, with ongoing cases in Shanghai and Jilin[152] - The company is actively managing its legal risks and has engaged in mediation to resolve disputes amicably[152] Business Operations and Strategy - The company is engaged in the pharmaceutical industry, focusing on the production of traditional Chinese medicine and modern pharmaceuticals[31] - The pharmaceutical sector is increasingly important due to the growing demand driven by an aging population and rising healthcare needs[30] - The company is focusing on developing new products, including a low oil absorption white carbon black to meet customer needs and enhance market competitiveness[52][53] - The company is actively involved in the sale of health foods and cosmetics, diversifying its revenue streams[70] - The company is focusing on research and development in fine chemical products and silicon materials, aiming to enhance its product offerings[71] Shareholder and Governance - The company has a board of 5 directors, including 2 independent directors, complying with legal and regulatory requirements[85] - The company has a supervisory board consisting of 3 supervisors, including 1 employee representative, also in compliance with legal and regulatory requirements[86] - The total remuneration paid to the board of directors, supervisors, and senior management in 2024 amounted to 4.2577 million CNY[105] - The company has established a performance evaluation and incentive mechanism linking management compensation to operational performance and key management indicators[85] - The company ensures strict compliance with information disclosure regulations, providing timely and accurate information to stakeholders[86] Future Outlook - The company has outlined a future outlook with a projected revenue growth target of 36.93% for the upcoming fiscal year[93] - The company plans to enhance its research and development efforts, focusing on innovative solutions to meet market demands[93] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, targeting a completion date by Q4 2025[101] - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels by the end of 2025[101] Employee and Training - The total number of employees at the end of the reporting period is 900, with 471 in production, 135 in sales, 90 in technical roles, 28 in finance, and 176 in administration[115] - The company conducts weekly training sessions for employees on production skills and safety knowledge[116] Environmental and Social Responsibility - The company emphasizes environmental protection and social responsibility in its operations, aiming for a balance between economic and social benefits[130] - The company respects and protects the rights of stakeholders, balancing the interests of shareholders, employees, and society[86]

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...

智通财经记者 | 黄华 智通财经编辑 | 谢欣 4月24日，吉药控股（证券简称：*ST吉药）公告称，公司收到终止上市事先告知书。公司股价在3月26日至4月23日期 间，连续20交易日股票收盘价均低于1元，触及创业板股票终止上市情形。 截至4月24日，吉药控股的股价仅为0.21元/股，总市值1.4亿元。 吉药控股最初的业务并非医药，其前身为双龙股份（全称"通化双龙化工股份有限公司"），生产白炭黑。这是一种以硅 砂为主要原料生产的功能性材料，可应用在国防等领域。双龙股份也曾是神舟系列载人飞船的材料供应商，它于2010年 上市。 上市之际，吉药控股的控股股东、实控人为卢忠奎。卢忠奎的简历显示，他于1958年6月出生，是吉林通化人。虽然吉 药控股如今一败涂地，但卢忠奎的人生曾出现过"草根逆袭"。据《中国日报》2013年5月发布的《通化市扶持中小企业 发展纪实》，卢忠奎命运的转折点可追溯至上世纪90年代。 1991年，农民卢忠奎被区政府任命为通化二道江区洗煤厂厂长。上任当年，他带领洗煤厂走出亏损局面，并在次年打破 利税150万元大关。后来，这家洗煤厂在兼并当地二化工厂后逐步成长为上市公司双龙股份。 在《中国日报》这篇报 ...

又一家公司锁定面值退市。 4月23日晚间，吉药控股集团股份有限公司（300108.SZ，下称"*ST吉药"）发布公告，称截至2025年4月23日，公司因股票连续20个交易日收盘 价低于1元，触发深交所终止上市规则，公司股票将被终止上市。 同时，公司股票将于4月24日开市起停牌，因触及交易类强制退市情形，而被深圳证券交易所作出终止上市决定的股票，不进入退市整理期。 制图：佘诗婕 五年亏损超32亿 就业绩层面来看，*ST吉药自2019年起连续5年亏损，2019年至2023年，公司归母净利润累计亏损超32亿元，2024年前三季度再亏2.31亿元。 截至2024年年末，净资产预计为-11.8亿至-8.3亿元，同时存在财务类退市风险。并且截至2024年9月30日，公司负债率攀升至161.77%，流动比 率仅0.16。 制图：李昕 根据东方财富Choice数据，公司前身为通化双龙化工股份有限公司，主营国防化工用白炭黑生产。2014年通过收购金宝药业转型医药领域，形 成"化工+医药"双主业模式。 2017年更名为吉药控股后，公司便开启了激进并购的模式，三年内收购普华制药、亚利大胶丸等十余家企业，业务覆盖医药工业、商业、研发 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2025-060 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 吉药控股集团股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日收到 深圳证券交易所下发的《事先告知书》（创业板函〔2025〕第 119 号），深圳证 券交易所拟决定终止公司股票上市交易。现将有关内容公告如下： 一、《事先告知书》具体内容 2025 年 3 月 26 日至 2025 年 4 月 23 日期间，你公司连续二十个交易日的股 票收盘价均低于 1 元，触及本所《创业板股票上市规则（2024 年修订）》第 10.2.1 条第一款第二项规定的股票终止上市情形，本所拟决定终止你公司股票上市交易。 根据本所《创业板股票上市规则（2024 年修订）》《自律监管听证程序细 则（2023 年修订）》等相关规定，你公司有权申请听证或者提出书面陈述和申 辩。申请听证的，你公司应当在收到本告知书之日起五个交易日内，以书面形式 向我部提出申请，并载明具体事项及理由。提出陈述和申辩的，你公司应当在收 到本告知书之日起十个交易日内，向本所提 ...

多家公司与之情况类似，在经营受困或者重大违法违规的情况下，率先因触及面值退市情形而将告别A 股。今年以来已有*ST东方（600811.SH）、*ST富润（600070.SH）、*ST嘉寓（300117.SZ）、*ST旭 蓝（000040.SZ）收到股票终止上市事先告知书。此外，*ST鹏博（600804.SH）股价已连续7个交易日 低于1元/股。 *ST吉药多次卖壳自救未遂，锁定退市结局 自今年3月26日每股股价低于1元之后，*ST吉药的股价便一路震荡下行，到4月16日之后每日股价跌幅 均超过10%，甚至跌停。最后一个交易日4月23日，该公司股价大跌12.50%。 上市近15年的*ST吉药（300108.SZ）宣告将退市，于4月24日开市起停牌，直至摘牌告别A股。 截至4月23日，*ST吉药股价连续20个交易日股票收盘价均低于1元，触及面值退市情形。这类触及交易 类强制退市情形的股票不进入退市整理期，在被交易所判定退市后，在15个交易日内摘牌。 *ST吉药难逃退市命运，即便不被投资者用脚投票投出市场，也可能因为净资产为负值而被终止上市。 该公司自2019年开始业绩连年亏损，经营承压，多次谋划易主，甚至计划破产重 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2025-059 吉药控股集团股份有限公司 关于股票交易异常波动暨严重异常波动公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、吉药控股集团股份有限公司（以下简称"公司"）股票连续 2 个交易日 （2025 年 4 月 22 日、4 月 23 日）收盘价格跌幅偏离值累计达到 30%，根据深 圳证券交易所相关规定，属于股票交易异常波动的情形。 2、公司股票连续 4 个交易日（2025 年 4 月 18 日、4 月 21 日、4 月 22 日、 4 月 23 日）收盘价格跌幅偏离值累计达到 50%，根据深圳证券交易所相关规定， 属于股票交易严重异常波动的情形。 3、截至 2025 年 4 月 23 日，公司连续二十个交易日出现股票收盘价均低于 1 元，已触及《深圳证券交易所创业板股票上市规则》第 10.2.1 条规定的终止上 市情形，公司股票将被终止上市。 4、公司股票将自 2025 年 4 月 24 日（星期四）开市起停牌。因触及交易类 强制退市情形而被深圳证券交易所作出终止上市决定 ...